// App-Quantinova.ai

ABS170 : REAL WORLD BLEEDING RATES OVER 7 YEARS OF ANTIHEMOPHILIC FACTOR (RECOMBINANT) IN PATIENTS WITH HEMOPHILIA A AND TARGET JOINTS: AHEAD INTERNATIONAL

Researchers

Presenter

  • M. C. Ozelo

Principal Investigators

  • D. A. Tsakiris

  • R. Klamroth

  • B. Guillet

  • K. Khair

  • A. Huth-Khne

  • K. Kurnik

  • S. Regensburger

  • J. Botha

  • A. Fernandez

  • L. Tang

  • J. Oldenburg

Medical Centers

  • Neurology, University of Campinas, Campinas, Brazil

  • University Hospital Basel, Basel, Switzerland

  • Department for Internal Medicine, Vascular Medicine and Haemostaseology, Vivantes Klinikum Friedrichshain, Berlin, Germany

  • Hemophilia Treatment Centre, Inserm U1085 IRSET, University Hospital of Rennes, Rennes, France

  • Centre for Outcomes and Experience Research in Children's Health, Illness and Disability (ORCHID), Great Ormond Street Hospital for Children, NHS Foundation Trust, London, United Kingdom

  • SRH Kurpfalzkrankenhaus and Haemophilia Centre Heidelberg GmbH, Heidelberg

  • Dr. von Haunersches Kinderspital Klinikum der Universität München, München, Germany

  • Takeda Pharma Vertrieb GmbH & Co. KG,Berlin,Germany

  • Takeda Pharmaceutical International AG, Zürich, Switzerland

  • Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany

Locations

  • Brazil

  • Switzerland

  • Germany

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • Antihemophilic factor

Outcome

  • N/A

Study Design

  • Multinational

  • Multicenteric

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • NCT02078427

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved